OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Lopes on the Rationale to Stop Immunotherapy After 2 Years in Lung Cancer

May 21st 2020

Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.

Dr. Chaft on the Emergence of Immunotherapy in Stage IV Lung Cancer

May 21st 2020

Jamie E. Chaft, MD, discusses the emergence of immunotherapy in stage IV lung cancer.

Dr. Klein on Oncotype DX in Predicting Outcomes in African Americans With Prostate Cancer

May 21st 2020

Eric A. Klein, MD, discusses the utility of Oncotype DX Genomic Prostate Score in predicting outcomes in African American men with prostate cancer.

Dr. Lewin on the Impact of COVID-19 on Cancer Care

May 20th 2020

Sharyn Lewin, MD, FACS, discusses the impact of the coronavirus disease 2019 (COVID-19) on cancer care.

Dr. Grossbard on the Role of Maintenance Rituximab in Follicular Lymphoma

May 20th 2020

Michael L. Grossbard, MD, discusses the role of maintenance rituximab (Rituxan) in follicular lymphoma.

Dr. Parikh on the Role of Radiation in HCC

May 20th 2020

Neehar Parikh, MD, discusses the role of radiation in hepatocellular carcinoma (HCC).

Dr. Lopes on the Rationale to Stop Immunotherapy After 2 Years in Lung Cancer

May 20th 2020

Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.

Dr. Brufsky on the Risk COVID-19 Poses to Patients With Cancer

May 20th 2020

Adam M. Brufsky, MD, PhD, discusses the risk the coronavirus disease 2019 poses to patients with cancer.

Dr. Chaft on the Emergence of Immunotherapy in Stage IV Lung Cancer

May 20th 2020

Jamie E. Chaft, MD, discusses the emergence of immunotherapy in stage IV lung cancer.

Dr. Subbiah on the Utility of Tivozanib in RCC

May 20th 2020

Vivek Subbiah, MD, discusses the utility of tivozanib in renal cell carcinoma.

Dr. Voorhees on the Benefit of Monoclonal Antibodies in Myeloma

May 20th 2020

Peter Voorhees, MD, discusses the benefit of monoclonal antibodies in multiple myeloma.

Dr. Jain on Response and Resistance to Venetoclax in Relapsed/Refractory MCL

May 20th 2020

Preetesh Jain, MD, PhD, discusses response and resistance to venetoclax (Venclexta) in relapsed/refractory mantle cell lymphoma (MCL).

Dr. Bahlis on Updated Data From the MAIA Trial in Multiple Myeloma

May 20th 2020

Nizar J. Bahlis, MD, discusses updated data from the phase 3 MAIA trial in multiple myeloma.

Dr. Bryce on the FDA Approval of Rucaparib in BRCA-Mutant mCRPC

May 20th 2020

Alan H. Bryce, MD, discusses the accelerated approval of rucaparib (Rubraca) for the treatment of adult patients with BRCA mutation (germline and/or somatic)–associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor–directed therapy and a taxane-based chemotherapy.

Dr. Hidalgo Medina on Promising Research in Pancreatic Cancer

May 20th 2020

Manuel Hidalgo Medina, MD, PhD, discusses some of the exciting research presented at the 2020 ACCR Virtual Annual Meeting I.

Dr. Bazhenova on the PACIFIC Trial With Durvalumab in NSCLC

May 20th 2020

Lyudmila A. Bazhenova, MD, discusses the PACIFIC study with durvalumab in stage III non–small-cell lung cancer.

Dr. Klein on the Importance of the Importance of Prognostic Genomic Assays in Prostate Cancer

May 20th 2020

Eric A. Klein, MD, discusses the importance of providing genomic testing to patients with prostate cancer.

Dr. Morris on the Role of Immunotherapy in Metastatic CRC

May 20th 2020

Van K. Morris, MD, discusses the role of immunotherapy in metastatic colorectal cancer.

Dr. Agarwal on the FDA Approval of Olaparib in HRR-Mutant mCRPC

May 19th 2020

Neeraj Agarwal, MD, discusses the FDA approval of olaparib (Lynparza) as a treatment for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer who have progressed following prior treatment with enzalutamide (Xtandi) or abiraterone acetate (Zytiga).

Dr. Bahlis on Updated Data From the MAIA Trial in Multiple Myeloma

May 19th 2020

Nizar J. Bahlis, MD, discusses updated data from the phase 3 MAIA trial in multiple myeloma.